Ocugen (OCGN) traded higher in the premarket on Thursday after the company said that OCU410, its gene therapy for an eye ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

Please provide your email address to receive an email when new articles are posted on . Vision-related quality of life is primarily dependent on the eye with better vision. An analysis found the inner ...

GA lesions, which form on the retina due to degeneration of pigment epithelium and photoreceptors, significantly impact daily functioning. This analysis assessed how functional and structural ...

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A single injection of the implant demonstrated reduced ...

Oral gildeuretinol demonstrated a statistically significant reduction in the geographic atrophy (GA) lesion growth rate of 15.3% from 6 to 24 months (p=0.047) in a pre-specified analysis.

A real-world retrospective study has shown that patients experiencing progressive daily vision loss from geographic atrophy (GA), a late form of nonexudative age-related macular degeneration, may ...

PURCHASE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported topline results ...

Today, the company announced that the first of these drugs, K8, delivered via a sustained release intraocular implant for the treatment of Geographic Atrophy (GA), reduced GA lesion area growth by ...